Gritstone Bio Inc 's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Gritstone Bio Inc 's ROA in the second quarter of 2024?
Gritstone Bio Inc recorded a cumulative net loss of $-201 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -124.71%.

However, within the Healthcare sector 893 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 4750, from total ROA ranking in the first quarter of 2024 at 4796.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Total Assets Change	-35.45 %	-30.4 %	-23.48 %	-6.9 %	4.43 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-201	-213	-138	-71	-63
Return On Assets (TTM)	-124.71 %	-117.77 %	-70.76 %	-33.91 %	-29.38 %
GRTS's Total Ranking	# 4750	# 4796	# 5234	# 4164	# 4147
Total Assets (TTM) in million	143	137	178	187	221
Seq. Total Assets Change	3.88 %	-22.79 %	-5.07 %	-15.22 %	12.02 %
Seq. Net Income Change	-	-	-	-	-

GRTS's 5 Years Annual ROA >> Back to GRTS Management Effectiveness >> Compare GRTS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 139
Sector	# 894
Overall	# 4667

Return On Assets Statistics
High	Average	Low
-26.11 %	-52.31 %	-124.7 %
(Mar 31 2023)		(Jun 30 2024)

Financial Statements
Gritstone Bio Inc 's Assets	$ 143 million	GRTS's Balance sheet
Gritstone Bio Inc 's Income	$ -23 million	Quarterly GRTS's Income Statement
GRTS's Income by Division		See GRTS's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-23.48 %	-16.41 %	26.58 %	19.04 %	-1.46 %
Total Assets in million	178	232	278	219	184
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-138	-120	-75	-105	-94
Annual Return On Assets	-77.93 %	-51.54 %	-27.02 %	-47.98 %	-51.21 %

GRTS's 5 Years Annual ROA >> Back to GRTS Management Effectiveness >> Compare GRTS ROA to its Competitors

More Return On Assets Ratios
GRTS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GRTS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GRTS's Competitors
Subscribers only: Roa for Gritstone Bio Inc 's Suppliers
Subscribers only: Return On Assets for GRTS's Customers

You may also want to know
GRTS's Roi	GRTS's Inventory Turnover Ratio	GRTS's Growth Rates	GRTS's Dividend Comparisons
	GRTS's Profitability Ratios	GRTS's Asset Turnover Ratio	GRTS's Dividend Growth
GRTS's Roe	GRTS's Valuation Ratios	GRTS's Financial Strength Ratios	GRTS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.